PDL BioPharma Inc. (NASDAQ:PDLI) went down by -18.94% from its latest closing price compared to the recent 1-year high of $3.78. The company’s stock price has collected -20.18% of loss in the last five trading sessions. Press Release reported on 10/02/20 that PDL BioPharma Completes Spin-Off of LENSAR
Is It Worth Investing in PDL BioPharma Inc. (NASDAQ :PDLI) Right Now?
Plus, the 36-month beta value for PDLI is at 1.07. Opinions of the stock are interesting as 0 analysts out of 1 who provided ratings for PDL BioPharma Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.”
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The average price from analysts is $2.78. PDLI currently public float of 110.01M and currently shorts hold a 11.91% ratio of that float. Today, the average trading volume of PDLI was 1.07M shares.
PDLI’s Market Performance
PDLI stocks went down by -20.18% for the week, with a monthly drop of -22.78% and a quarterly performance of -10.92%, while its annual performance rate touched 41.30%. The volatility ratio for the week stands at 6.35% while the volatility levels for the past 30 days are set at 4.72% for PDL BioPharma Inc.. The simple moving average for the period of the last 20 days is -19.74% for PDLI stocks with a simple moving average of -10.68% for the last 200 days.
Analysts’ Opinion of PDLI
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see PDLI reach a price target of $4, previously predicting the price at $5. The rating they have provided for PDLI stocks is “Sector Perform” according to the report published on February 23rd, 2016.
RBC Capital Mkts gave a rating of “Sector Perform” to PDLI, setting the target price at $5 in the report published on February 02nd of the previous year.
PDLI Trading at -20.42% from the 50-Day Moving Average
After a stumble in the market that brought PDLI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -30.95% of loss for the given period.
Volatility was left at 4.72%, however, over the last 30 days, the volatility rate increased by 6.35%, as shares sank -22.09% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -14.98% lower at present.
During the last 5 trading sessions, PDLI fell by -20.18%, which changed the moving average for the period of 200-days by -18.44% in comparison to the 20-day moving average, which settled at $3.21. In addition, PDL BioPharma Inc. saw -3.11% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at PDLI starting from PDL BIOPHARMA, INC., who purchase 8,703 shares at the price of $11.16 back on Sep 29. After this action, PDL BIOPHARMA, INC. now owns 8,667,397 shares of PDL BioPharma Inc., valued at $97,125 using the latest closing price.
Stock Fundamentals for PDLI
Current profitability levels for the company are sitting at:
- -121.55 for the present operating margin
- -9.44 for the gross margin
The net margin for PDL BioPharma Inc. stands at -128.59. The total capital return value is set at -9.01, while invested capital returns managed to touch -9.54.
Based on PDL BioPharma Inc. (PDLI), the company’s capital structure generated 4.88 points at debt to equity in total, while total debt to capital is 4.65. Total debt to assets is 4.04, with long-term debt to equity ratio resting at 4.72. Finally, the long-term debt to capital ratio is 4.50.
When we switch over and look at the enterrpise to sales, we see a ratio of 4.03, with the company’s debt to enterprise value settled at 0.13. The receivables turnover for the company is 0.70 and the total asset turnover is 0.07. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.87.